Association of Rivaroxaban with Thromboembolic Events in Patients with Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial

JAMA Cardiology

Volumn 4, Issue 6, 2019, Pages 515-523

  Greenberg, Barry ^a   Neaton, James D ^b   Anker, Stefan D ^c,d   Byra, William M ^e   Cleland, John G F ^f,g   Deng, Hsiaowei ^e   Fu, Min ^h   La Police, David A ^e   Lam, Carolyn S P ^i,j,k   Mehra, Mandeep R ^l   Nessel, Christopher C ^e   Spiro, Theodore E ^m   Van Veldhuisen, Dirk J ^k   Vanden Boom, Catherine M ^e   Zannad, Faiez ^n,o  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ DEPARTMENT OF CARDIOLOGY   (Singapore)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m Bayer US   (United States)

ⁿ UNIVERSITÉ DE LORRAINE   (France)

^o UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PLACEBO; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ARTICLE; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; SINUS RHYTHM; SUDDEN DEATH; THROMBOEMBOLISM; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; VEIN THROMBOSIS;

AGED; ASPIRIN; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DEATH, SUDDEN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FACTOR XA INHIBITORS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PULMONARY EMBOLISM; RIVAROXABAN; STROKE; STROKE VOLUME; THIENOPYRIDINES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 85065325850     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2019.1049     Document Type: Article

References (28)

1. Mega JL, Braunwald E, Wiviott SD,; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366 (1): 9-19. doi: 10.1056/NEJMoa1112277 22077192
2. Eikelboom JW, Connolly SJ, Bosch J,; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377 (14): 1319-1330. doi: 10.1056/NEJMoa1709118 28844192
3. Korjian S, Braunwald E, Daaboul Y, Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 Trial). Am J Cardiol. 2018; 122 (11): 1896-1901. doi: 10.1016/j.amjcard.2018.08.034 30340765
4. Branch KR. Rivaroxaban plus aspirin in patients with and without heart failure and chronic coronary or peripheral artery disease: the COMPASS trial. Paper resented at: Heart Failure 2018 & World Congress on Acute Heart Failure; May 28, 2018; Vienna, Austria.
5. Zannad F, Anker SD, Byra WM,; COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018; 379 (14): 1332-1342. doi: 10.1056/NEJMoa1808848 30146935
6. Lee DS, Austin PC, Stukel TA, "Dose-dependent" impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med. 2009; 122 (2): 162-169.e1. doi: 10.1016/j.amjmed.2008.08.026 19100960
7. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011; 306 (15): 1669-1678. doi: 10.1001/jama.2011.1474 22009099
8. Fonarow GC, Stough WG, Abraham WT,; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50 (8): 768-777. doi: 10.1016/j.jacc.2007.04.064 17707182
9. Solomon SD, Dobson J, Pocock S,; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116 (13): 1482-1487. doi: 10.1161/CIRCULATIONAHA.107.696906 17724259
10. Bettari L, Fiuzat M, Becker R, Felker GM, Metra M, O'Connor CM. Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. Circ Heart Fail. 2011; 4 (3): 361-368. doi: 10.1161/CIRCHEARTFAILURE.110.959957 21586736
11. Uretsky BF, Thygesen K, Armstrong PW, Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000; 102 (6): 611-616. doi: 10.1161/01.CIR.102.6.611 10931799
12. Loh E, Sutton MS, Wun CC, Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997; 336 (4): 251-257. doi: 10.1056/NEJM199701233360403 8995087
13. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995; 92 (7): 1701-1709. doi: 10.1161/01.CIR.92.7.1701 7671351
14. Acharya T, Aspelund T, Jonasson TF, Association of unrecognized myocardial infarction with long-term outcomes in community-dwelling older adults: the ICELAND MI study. JAMA Cardiol. 2018; 3 (11): 1101-1106. doi: 10.1001/jamacardio.2018.3285 30304454
15. Schwartz RS, Burke A, Farb A, Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology. J Am Coll Cardiol. 2009; 54 (23): 2167-2173. doi: 10.1016/j.jacc.2009.07.042 19942088
16. Schmemund SA, Schwartz RS, Adamzik M, Coronary atherosclerosis in unheralded sudden coronary death under age 50: histo-pathologic comparison with 'healthy' subjects dying out of hospital. Atherosclerosis. 2001; 155: 499-508.
17. Zannad F, Greenberg B, Cleland JGF, Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail. 2015; 17 (7): 735-742. doi: 10.1002/ejhf.266 25919061
18. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989; 84 (408): 1065-1073. doi: 10.1080/01621459.1989.10478873
19. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 1998; 31 (4): 749-753. doi: 10.1016/S0735-1097(98)00006-0 9525542
20. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006; 8 (4): 428-432. doi: 10.1016/j.ejheart.2006.02.012 16737850
21. Cleland JG, Findlay I, Jafri S, The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004; 148 (1): 157-164. doi: 10.1016/j.ahj.2004.03.010 15215806
22. Massie BM, Collins JF, Ammon SE,; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009; 119 (12): 1616-1624. doi: 10.1161/CIRCULATIONAHA.108.801753 19289640
23. Homma S, Thompson JL, Pullicino PM,; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012; 366 (20): 1859-1869. doi: 10.1056/NEJMoa1202299 22551105
24. Treasure CB, Vita JA, Cox DA, Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990; 81 (3): 772-779. doi: 10.1161/01.CIR.81.3.772 2306829
25. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993; 14 (2): 205-212. doi: 10.1093/eurheartj/14.2.205 8449196
26. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999; 33 (5): 1424-1426. doi: 10.1016/S0735-1097(99)00033-9 10193748
27. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001; 103 (13): 1746-1751. doi: 10.1161/01.CIR.103.13.1746 11282905
28. Gheorghiade M, Thyssen A, Zolynas R, Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. J Heart Lung Transplant. 2011; 30 (2): 218-226. doi: 10.1016/j.healun.2010.08.027 20947383